Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Seremax Forte
- Development stage
- Unknown
- Lead developer
- Iberica Verheilen Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Seremax Forte is an oral combination pharmaceutical developed and marketed by Iberica Verheilen Pharmaceuticals (IVP Pharma). It is formulated as a capsule containing three active ingredients: pregabalin (75 mg), mecobalamin (750 mcg), and alpha lipoic acid (100 mg). Pregabalin is a small molecule gamma-aminobutyric acid (GABA) analogue that acts as an anticonvulsant and analgesic by binding to the auxiliary α2-δ subunit of voltage-gated calcium channels in the central nervous system, thereby reducing the release of excitatory neurotransmitters. Mecobalamin, a form of vitamin B12, supports nerve regeneration and myelin sheath formation, while alpha lipoic acid serves as a potent antioxidant to protect nerve cells from oxidative damage. The drug is primarily indicated for the management of neuropathic pain associated with diabetic neuropathy and post-herpetic neuralgia, and it is also used as an anticonvulsant for treating epileptic seizures.
- Brand names
- Seremax Forte
- Other names
- SEREMAX FORTE Capsule
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (α2δ-2)
Beyond the preview
Go deeper on Seremax Forte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seremax Forte.